Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

LCTX | Lineage Cell Therapeutics Inc

Index	RUT	P/E	-	EPS (ttm)	-0.13	Insider Own	0.39%	Shs Outstand	174.99M	Perf Week	-10.08%
Market Cap	202.99M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	0.00%	Shs Float	174.30M	Perf Month	-14.07%
Income	-22.02M	PEG	-	EPS next Q	-0.05	Inst Own	48.75%	Short Float / Ratio	3.54% / 13.16	Perf Quarter	-15.33%
Sales	10.52M	P/S	19.30	EPS this Y	-6.67%	Inst Trans	0.01%	Short Interest	6.18M	Perf Half Y	-16.55%
Book/sh	0.42	P/B	2.78	EPS next Y	-2.68%	ROA	-17.79%	Target Price	5.50	Perf Year	-1.69%
Cash/sh	0.26	P/C	4.42	EPS next 5Y	-	ROE	-28.32%	52W Range	1.02 - 1.58	Perf YTD	-0.85%
Dividend	-	P/FCF	-	EPS past 5Y	1.87%	ROI	-29.33%	52W High	-26.58%	Beta	1.69
Dividend %	-	Quick Ratio	3.02	Sales past 5Y	115.81%	Gross Margin	87.74%	52W Low	13.73%	ATR	0.05
Employees	78	Current Ratio	3.02	Sales Q/Q	-29.17%	Oper. Margin	-223.83%	RSI (14)	27.38	Volatility	4.20% 3.97%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	23.12%	Profit Margin	-209.27%	Rel Volume	0.73	Prev Close	1.18
Shortable	Yes	LT Debt/Eq	0.03	Earnings	Aug 10 AMC	Payout	-	Avg Volume	469.28K	Price	1.16
Recom	1.43	SMA20	-12.02%	SMA50	-15.48%	SMA200	-15.31%	Volume	344,082	Change	-1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-02-22	Initiated	Robert W. Baird	Outperform	$5
Jun-14-22	Initiated	B. Riley Securities	Buy	$4
Aug-19-21	Initiated	Noble Capital Markets	Outperform	$8
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight	$6

Sep-19-23 08:00AM	Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023 (Business Wire)
Sep-13-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress (Business Wire)
Sep-11-23 08:00AM	Lineage to Present at 2023 International Spinal Research Trust Network Meeting (Business Wire)
Sep-06-23 09:40AM	EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics (Benzinga)
08:00AM	Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics (Business Wire)
08:00AM	Loading…
Aug-29-23 08:00AM	Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference (Business Wire)
Aug-13-23 06:39AM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 09:43AM	Q2 2023 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:15PM	Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Aug-09-23 08:50AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-08-23 06:40PM	U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates (Zacks)
Aug-03-23 08:00AM	Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (Business Wire)
Jul-24-23 08:00AM	Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer (Business Wire)
May-22-23 08:00AM	Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index (Business Wire)
12:02PM	Loading…
May-16-23 12:02PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 05:35PM	Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-09-23 08:00AM	Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Business Wire)
May-04-23 06:15PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
08:00AM	Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 (Business Wire)
Apr-26-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire)
Apr-18-23 08:00AM	Lineage to Present at 2023 AAPS National Biotechnology Conference (Business Wire)
Apr-10-23 07:57PM	3 Penny Stocks to Buy During Market Downturns (InvestorPlace)
Mar-30-23 08:00AM	Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium (Business Wire)
Mar-28-23 03:57PM	Top 10 Growth Stocks in Biotech (Insider Monkey)
Mar-20-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit (Business Wire)
Mar-11-23 03:00AM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-10-23 06:33AM	Q4 2022 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-09-23 05:25PM	Lineage Cell (LCTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (Business Wire)
Mar-06-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. (Business Wire)
Mar-02-23 09:55AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 (Business Wire)
Feb-22-23 09:46AM	EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology (Benzinga)
08:00AM	Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (Business Wire)
Feb-08-23 08:00AM	Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss (Business Wire)
Nov-29-22 08:00AM	Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference (Business Wire) +5.76%
Nov-28-22 08:00AM	Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire)
Nov-17-22 12:00PM	What Makes Lineage Cell (LCTX) a New Buy Stock (Zacks) +10.69%
09:45AM	2 Strong Buy Penny Stocks That Could See 200% Gains (Or More) (TipRanks)
Nov-10-22 06:35PM	Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +6.40%
04:05PM	Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-08-22 05:45PM	Berkeley Lights, Inc. (BLI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-22 08:00AM	Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022 (Business Wire)
Oct-31-22 08:00AM	Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer (Business Wire) +9.52%
Oct-10-22 08:00AM	Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells (Business Wire)
Oct-04-22 08:00AM	Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa (Business Wire) +7.02%
Oct-03-22 08:00AM	Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel (Business Wire)
07:41AM	EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility (Benzinga)
Sep-19-22 07:00AM	The Three Best Anti-Aging Stocks to Buy in September (InvestorPlace) -5.43%
Aug-15-22 08:00AM	Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference (Business Wire)
Aug-12-22 09:30AM	10 Best One Dollar Stocks To Buy Now (Insider Monkey)
02:31AM	Lineage Cell Therapeutics, Inc. (LCTX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-11-22 04:05PM	Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-08-22 06:05PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.19%
Aug-04-22 08:00AM	Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022 (Business Wire) +8.59%
Jul-14-22 08:45AM	10 Best Penny Stocks to Buy in July (Insider Monkey)
Jun-02-22 08:00AM	Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology (Business Wire) +6.50%
May-16-22 10:25AM	Lineage Cell Therapeutics, Inc. (LCTX) Q1 2022 Earnings Call Transcript (Motley Fool)
May-12-22 06:05PM	Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-11-22 05:55PM	BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.75%
May-10-22 10:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +7.50%
May-05-22 05:25PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.46%
08:00AM	Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022 (Business Wire)
May-03-22 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire) +7.50%
Apr-26-22 08:00AM	Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022 (Business Wire)
Apr-25-22 08:00AM	Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness (Business Wire) +11.86%
Apr-13-22 08:00AM	Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer (Business Wire) +5.60%
Apr-11-22 08:00AM	Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022 (Business Wire)
Mar-24-22 08:00AM	Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022 (Business Wire)
Mar-21-22 10:14AM	YmAbs Therapeutics, Inc. (YMAB) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
08:00AM	Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss (Business Wire)
Mar-14-22 08:00AM	RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS (Business Wire) -5.97%
Mar-10-22 06:25PM	Lineage Cell (LCTX) Reports Q4 Loss (Zacks)
04:05PM	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire)
Mar-01-22 08:00AM	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022 (Business Wire)
Feb-28-22 05:25PM	Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Jan-24-22 08:00AM	Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022 (Business Wire) +5.73%
Jan-04-22 08:00AM	Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference (Business Wire) -8.47%
Dec-20-21 06:03PM	Why Lineage Cell Therapeutics Zoomed Higher Today (Motley Fool) +21.23%
05:02PM	Genentech pays $50M upfront for cell therapy deal targeting eye diseases (American City Business Journals)
06:00AM	Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders (Business Wire)
Nov-30-21 08:00AM	Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen® (Business Wire) +13.00%
Nov-15-21 08:00AM	OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D. (Business Wire)
Nov-11-21 09:01PM	Lineage Cell Therapeutics, Inc. (LCTX) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-10-21 06:45PM	Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs (Business Wire)
Nov-03-21 08:00AM	Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021 (Business Wire)
Oct-27-21 03:04PM	Analysts Estimate Lineage Cell (LCTX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-26-21 08:00AM	OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. (Business Wire)
Oct-21-21 10:31AM	Lineage, Pioneering a New Branch of Medicine OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy (Benzinga)
Oct-20-21 10:38AM	Lineage, Pioneering a New Branch of Medicine OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy (Benzinga)
Oct-18-21 08:00AM	Lineage to Be Featured in B. Riley Securities Fall 2021 "Growth Biotech Best Ideas" Virtual Series on October 18, 2021 (Business Wire)
Sep-30-21 10:52AM	Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D. (Business Wire)
Sep-20-21 08:00AM	Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 (Business Wire) -7.84%
Sep-15-21 09:00AM	Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy (Business Wire) +9.73%
Sep-13-21 08:00AM	Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D. (Business Wire)
Sep-01-21 08:00AM	Lineage Announces Appointment of General Counsel (Business Wire)

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LCTX | Lineage Cell Therapeutics Inc

Upgrade your FINVIZ experience